News Archives

News Archives

Avivagen Announces Final Closing of Private Placement of Debentures and Shares

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/Business Wire/April 9, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human …Read More

Avivagen to Pursue Business Opportunities for Combining its Proprietary OxC-beta™ with Cannabis Products

Ottawa, ON / Business Wire/ April 3, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”, or the “Corporation”) is pleased to announce that it has begun to explore the combination of Avivagen’s proprietary OxC-beta™ product with licensed cannabis products. Recently Avivagen has received inbound expressions of interest in exploring such product combinations from multiple, large integrated …Read More

Avivagen Announces Closing of Private Placement of Debentures and Shares

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/Business Wire/March 28, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human …Read More

Avivagen Announces Proposed Private Placement of Debentures and Shares

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/BusinessWire/March 27, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and …Read More

Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2019

Ottawa, ON /GlobeNewswire/ March 6th, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) reported today its unaudited financial results for Q1 2019. For the three-month period ended January 31, 2019, the Corporation reported revenues of $322,125 – a doubling of revenues compared to revenues of $143,201 for the three-month period ended January 31, …Read More

Avivagen Announces Large Order for OxC-beta™ Livestock and Expansion into Additional Applications

Ottawa, ON /GlobeNewswire/ February 28, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”), is pleased to announce that its partner in the Philippines, UNAHCO, has purchased 2 metric tons of OxC-beta™ Livestock, and follows an order of 2 metric tons delivered to UNAHCO in November 2018.  UNAHCO forecasts demand to grow in 2019 as it expands …Read More